RegeneRx Biopharmaceuticals, Inc. Release: Researchers From Henry Ford Hospital Report In Neuroscience That TB4 Improves Neurological Function After Stroke

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (“the Company” or “RegeneRx”) today announced a research team from the Henry Ford Hospital in Detroit, MI, reported that Thymosin beta 4 (Tß4), administered to rats after embolic stroke, improved neurological functional outcome compared to control animals.